Activation of blood coagulation in autoimmune skin disorders

Expert Review of Clinical Immunology

Volumn 5, Issue 5, 2009, Pages 605-613

  Cugno, Massimo ^a   Tedeschi, Alberto ^b   Crosti, Carlo ^a   Marzano, Angelo V ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Blood coagulation; Bullous pemphigoid; Chronic urticaria; Psoriasis; Tissue factor

Indexed keywords

HEPARIN; INTERLEUKIN 6; THROMBIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; WARFARIN;

ANTICOAGULANT THERAPY; AUTOIMMUNE SKIN DISEASE; BLOOD CLOTTING; BLOOD VESSEL PERMEABILITY; BULLOUS PEMPHIGOID; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC URTICARIA; CYTOKINE PRODUCTION; DERMATITIS; DISEASE ASSOCIATION; ENTERITIS; HEPARINIZATION; HUMAN; INFLAMMATORY DISEASE; LUPUS ERYTHEMATOSUS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN BLOOD VESSEL; TISSUE INJURY;

EID: 77949840385     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.40     Document Type: Review

References (79)

1. Opal SM. Phylogenetic and functional relationships between coagulation and the innate immune response. Crit. Care Med. 28(Suppl.), S77-S80 (2000).
2. Esmon CT. The impact of the inflammatory response on coagulation. Thromb. Res. 114, 321-327 (2004).
3. Levi M, Van Der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc. Med. 15, 254-259 (2005).
4. Chu AJ. Tissue factor mediates inflammation. Arch. Biochem. Biophys. 440, 123-132 (2005).
5. Dhar J, Andersen J, Essenmacher L, Ager J, Bentley G, Sokol R. Thrombophilic patterns of coagulation factors in lupus. Lupus 18, 400-406 (2009).
6. Ingegnoli F, Fantini F, Favalli EG et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-α blockade. J. Autoimmun. 31, 175-179 (2008).
7. Borensztajn K, Peppelenbosch MP, Spek CA. Coagulation factor Xa signaling: the link between coagulation and inflammatory bowel disease? Trends Pharmacol. Sci. 30, 8-16 (2009).
8. Greaves M. Chronic urticaria. J. Allergy Clin. Immunol. 105, 664-672 (2000).
9. Grattan CE, Sabroe RA, Greaves MW. Chronic urticaria. J. Am. Acad. Dermatol. 46, 645-657 (2002).
10. Greaves MW, Tan KT. Chronic urticaria: recent advances. Clin. Rev. Allergy Immunol. 33, 134-143 (2007).
11. Gaig P, Olona M, Munoz Lejarazu D et al. Epidemiology of urticaria in Spain. J. Investig. Allergol. Clin. Immunol. 14, 214-220 (2004).
12. ODonnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br. J. Dermatol. 136, 197-201 (1997).
13. Shoemaker R. A search for the affective determinants of chronic urticaria. Psychosomatics 4, 125-132 (1963).
14. Rees L. An etiological study of chronic urticaria and angioneurotic oedema. J. Psychosom. Res. 2, 172 (1957).
15. Michaelsson G, Juhlin L. Urticaria induced by preservatives and dye additives in food and drugs. Br. J. Dermatol. 88, 525-532 (1973).
16. Greaves MW. Chronic idiopathic urticaria and H. pylori: not directly causative but could there be a link? ACI Internat. 13, 23-26 (2001).
17. Grattan CE, Wallington TB, Warin RP, Kennedy CT, Bradfield JW. A serological mediator in chronic idiopathic urticaria: a clinical, immunological and histological evaluation. Br. J. Dermatol. 114, 583-590 (1986).
18. Gruber BL, Baeza ML, Marchese MJ, Agnello V, Kaplan AP. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J. Invest. Dermatol. 90, 213-217 (1988).
19. Hide M, Francis DM, Grattan CEH, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. N. Eng. J. Med. 328, 1599-1604 (1993).
20. Kikuchi Y, Kaplan A. Mechanisms of autoimmune activation of basophils in chronic urticaria. J. Allergy Clin. Immunol. 107, 1056-1062 (2001).
21. Kikuchi Y, Kaplan A. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J. Allergy Clin. Immunol. 109, 114-118 (2002).
22. Soundararajan S, Kikuchi Y, Joseph K et al. Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. J. Allergy Clin. Immunol. 115, 815-821 (2005).
23. Puccetti A, Bason C, Simeoni S et al. In chronic idiopathic urticaria autoantibodies against FcηRII/CD23 induce histamine release via eosinophil activation. Clin. Exp. Allergy 35, 1599-1607 (2005).
24. Leznoff A, Sussman GL. Syndrome of idiopathic CU and angioedema with thyroid autoimmunity: a study of 90 patients. J. Allergy Clin. Immunol. 84, 66-71 (1989).
25. Turktas I, Gokcora N, Demirsoy S et al. The association of chronic urticaria and angioedema with autoimmune thyroiditis. Int. J. Dermatol. 36, 187-190 (1997).
26. ODonnell BF, Francis DM, Swana GT, Seed PT, Kobza Black A, Greaves MW. Thyroid autoimmunity in chronic urticaria. Br. J. Dermatol. 153, 331-335 (2005).
27. Kikuchi Y, Fann T, Kaplan A. Antithyroid antibodies in chronic urticaria and angioedema. J. Allergy Clin. Immunol. 112, 218 (2003).
28. Grattan CEH, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti IgE in chronic urticaria. Clin. Exp. Allergy 21, 695-704 (1991).
29. Fiebiger E, Maurer D, Holub H et al. Serum IgG autoantibodies directed against the αchain of FceRI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J. Clin. Invest. 96, 2606-2612 (1995).
30. Ferrer M, Kinet JP, Kaplan AP. Comparative studies of functional and binding assays for IgG anti-FcηRIα (α-subunit). J. Allergy Clin. Immunol. 101, 672-676 (1998).
31. Asero R, Tedeschi A, Lorini M, Salimbeni R, Zanolettooi T, Miadonna A. Chronic urticaria: novel clinical and serological aspects. Clin. Exp. Allergy 31, 1105-1110 (2001).
32. Fagiolo U, Kricek F, Ruf C, Peserico A, Amadori A, Cancian M. Effects of complement inactivation and IgG depletion on skin reactivity to autologous serum in chronic idiopathic urticaria. J. Allergy Clin. Immunol. 106, 567-572 (2000).
33. Asero R, Tedeschi A, Riboldi P, Cugno M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-andflare reactions much more frequently than autologous serum. J. Allergy Clin. Immunol. 117, 1113-1117 (2006).
34. Asero R, Tedeschi A, Coppola R et al. Activation of the tissue pathway of blood coagulation in patients with chronic urticaria. J. Allergy Clin. Immunol. 119, 705-710 (2007).
35. Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M. Severe chronic urticaria is associated with elevated plasma levels of d-dimer. Allergy 63, 176-180 (2008).
36. Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R. Expression of tissue factor by eosinophils in patients with chronic urticaria. Int. Arch. Allergy Immunol. 148, 170-174 (2009).
37. Moosbauer C, Morgenstern E, Cuvelier SL et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 109, 995-1002 (2007).
38. Schaeffer RC, Gong F, Bitrick MS, Smith TL. Thrombin and bradykinin initiate discrete endothelial solute permeability mechanisms. Am. J. Physiol. 264, 1798 - 1809 (1993).
39. Cirino G, Cicala C, Bucci MR, Sorrentino L, Maranganore JM, Stone SR. Thrombin functions as an inflammatory mediator through activation of its receptors. J. Exp. Med. 183, 821-827 (1996).
40. Nobe K, Sone T, Paul RJ, Honda K. Thrombin-induced force development in vascular endothelial cells: contribution to alteration of permeability mediated by calcium-dependent and -independent pathways. J. Pharmacol. Sci. 99, 252-263 (2005).
41. Razin E, Marx G. Thrombin-induced degranulation of cultured bone marrowderived mast cells. J. Immunol. 133, 3282-3285 (1984).
42. Vliagoftis H. Thrombin induces mast cell adhesion to fibronectin: evidence for the involvement of protease-activated receptor-1. J. Immunol. 169, 4551-4558 (2002).
43. Wang F, Tang H, Xu J, Kang K. Activation of the blood coagulation cascade is involved in patients with chronic urticaria. J. Allergy Clin. Immunol. 123, 972-973 (2009).
44. Khalaf AT, Liu XM, Sheng WX, Tan JQ, Abdalla AN. Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria. J. Eur. Acad. Dermatol. Venereol. 22, 487-492 (2008).
45. Fujii K, Usuki A, Kan-No Y, Ohgou N. Elevation of circulating thrombinantithrombin III complex and fibrin degradation products in urticaria. A laboratory finding unrelated to intravascular coagulopathy. J. Dermatol. 35, 308-310 (2008).
46. Schmidt E, Zillikens D. Autoimmune and inherited subepidermal blistering diseases: advances in the clinic and the laboratory. Adv. Dermatol. 16, 113-157 (2000).
47. Yancey KB. The pathophysiology of autoimmune blistering diseases. J. Clin. Invest. 115, 825-828 (2005).
48. Kaneko F, Minagawa T, Takiguchi Y, Suzuki M, Itoh N. Role of cell-mediated immune reaction in blister formation of bullous pemphigoid. Dermatology 184, 34-39 (1992).
49. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J. Clin. Invest. 116, 1159-1166 (2006).
50. Frezzolini A, Cianchini G, Ruffelli M, Cadoni S, Puddu P, De Pita O. Interleukin-16 expression and release in bullous pemphigoid. Clin. Exp. Immunol. 137, 595-600 (2004).
51. Frezzolini A, Teofoli P, Cianchini G et al. Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid. Eur. J. Dermatol. 12, 27-31 (2002).
52. Ameglio F, DAuria L, Bonifati C, Ferraro C, Mastroianni A, Giacalone B. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity. Br. J. Dermatol. 138, 611-614 (1998).
53. Borrego L, Maynard B, Peterson EA et al. Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. Am. J. Pathol. 148, 897-909 (1996).
54. Niimi Y, Pawankar R, Kawana S. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid. Int. Arch. Allergy Immunol. 139, 104-113 (2006).
55. Shimanovich I, Mihai S, Oostingh GJ et al. Granulocyte-derived elastase and gelatinase B are required for dermal- epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J. Pathol. 204, 519-527 (2004).
56. Ståhle-Bäckdahl M, Inoue M, Guidice GJ, Parks WC. 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J. Clin. Invest. 93, 2022-2030 (1994).
57. Marzano AV, Tedeschi A, Fanoni D et al. Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications. Br. J. Dermatol. 160, 266-272 (2009).
58. Garcia JG, Siflinger-Birnboim A, Bizios R, Del Vecchio PJ, Fenton JW 2nd, Malik AB. Thrombin-induced increase in albumin permeability across the endothelium. J. Cell. Physiol. 128, 96-104 (1986).
59. DeMichele MA, Moon DG, Fenton JW 2nd, Minnear FL. Thrombins enzymatic activity increases permeability of endothelial cell monolayers. J. Appl. Physiol. 69, 1599-1606 (1990).
60. Rosendaal FR, Van Hylckama Vlieg A, Doggen CJM. Venous thrombosis in the elderly. J. Thromb. Haemost. 5(Suppl. 1), 310-317 (2007).
61. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 370, 263-271 (2007).
62. Shelling ML, Federman DG, Prodanovich S, Kirsner RS. Psoriasis and vascular disease: an unsolved mystery. Am. J. Med. 121, 360-365 (2008).
63. Pietrzak AT, Zalewska A, Chodorowska G et al. Cytokines and anticytokines in psoriasis. Clin. Chim. Acta 394, 7-21 (2008).
64. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 296, 1735-1741 (2006).
65. Marongiu F, Sorano GG, Bibbò C et al. Abnormalities of blood coagulation and fibrinolysis in psoriasis. Dermatology 189, 32-37 (1994).
66. Karabudak O, Ulusoy RE, Erikci AA, Solmazgul E, Dogan B, Harmanyeri Y. Inflammation and hypercoagulable state in adult psoriatic men. Acta Derm. Venereol. 88, 337-340 (2008).
67. Liaw PC, Esmon CT, Kahnamoui K et al. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 104, 3958-3964 (2004).
68. Meyer-De Schmid JJ, Neuman A. Treatment of chronic urticaria with heparin. Bull. Soc. Fr. Dermatol. Syphiligr. 59, 286-287 (1952).
69. Chua SL, Gibbs S. Chronic urticaria responding to subcutaneous heparin sodium. Br. J. Dermatol. 153, 216-217 (2005).
70. Parslew R, Pryce D, Ashworth J, Friedmann PS. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin. Exp. Allergy 30, 1161-1165 (2000).
71. Mahesh PA, Pudupakkam VK, Holla AD, Dande T. Effect of warfarin on chronic idiopathic urticaria. Indian J. Dermatol. Venereol. Leprol. 75, 187-189 (2009).
72. Cicardi M, Bergamaschini L, Zingale LC, Gioffré D, Agostoni A. Idiopathic nonhistaminergic angioedema. Am. J. Med. 106, 650-654 (1999).
73. Tant D. Tranexamic acid in chronic urticaria. Br. Med. J. 1, 266 (1979).
74. Laurberg G. Tranexamic acid (cyklokapron) in chronic urticaria: a double-blind study. Acta Derm. Venereol. 57, 369-370 (1977).
75. Chacko MK, Mathew T, Sugathan P, Nair LV. Heparin in psoriasis. Indian J. Dermatol. Venereol. Leprol. 64, 273-274 (1998).
76. Liu CH. Warfarin in the treatment of psoriasis. Int. J. Dermatol. 31, 743-744 (1992).
77. Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch. Dermatol. 134, 465-469 (1998).
78. Joly P, Benichou J, Lok C et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch. Dermatol. 141, 691-698 (2005).
79. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br. J. Dermatol. 159, 895-902 (2008).